92 related articles for article (PubMed ID: 20698750)
1. The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells.
Hanusová V; Králová V; Schröterová L; Trilecová L; Pakostová A; Skálová L
Xenobiotica; 2010 Oct; 40(10):681-90. PubMed ID: 20698750
[TBL] [Abstract][Full Text] [Related]
2. The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A.
Hanušová V; Boušová I; Pakostová A; Skálová L
Xenobiotica; 2012 Jun; 42(6):571-9. PubMed ID: 22217270
[TBL] [Abstract][Full Text] [Related]
3. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
4. In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice.
Hanušová V; Tomšík P; Kriesfalusyová L; Pakostová A; Boušová I; Skálová L
Pharmacol Rep; 2013; 65(2):445-52. PubMed ID: 23744429
[TBL] [Abstract][Full Text] [Related]
5. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
[TBL] [Abstract][Full Text] [Related]
6. Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.
Hanušová V; Boušová I; Skálová L
Drug Metab Rev; 2011 Nov; 43(4):540-57. PubMed ID: 21942373
[TBL] [Abstract][Full Text] [Related]
7. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
9. Hexane/ethanol extract of Glycyrrhiza uralensis licorice suppresses doxorubicin-induced apoptosis in H9c2 rat cardiac myoblasts.
Choi HJ; Seon MR; Lim SS; Kim JS; Chun HS; Park JH
Exp Biol Med (Maywood); 2008 Dec; 233(12):1554-60. PubMed ID: 18849542
[TBL] [Abstract][Full Text] [Related]
10. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
11. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
Shin DH; Choi KS; Park SA; Cho BS; Lee HS; Ryu JS; Kim TY; Lee CK; Song S; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1355-61. PubMed ID: 18958428
[TBL] [Abstract][Full Text] [Related]
12. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
15. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
He QY; Meng FH; Zhang HQ
Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):179-81. PubMed ID: 9772674
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
17. Induction of cell death by Doxorubicin in multicellular spheroids as studied by confocal laser scanning microscopy.
Wartenberg M; Acker H
Anticancer Res; 1996; 16(2):573-9. PubMed ID: 8687100
[TBL] [Abstract][Full Text] [Related]
18. [Vectorisation of doxorubicin in nanospheres and reversion of pleiotropic resistance of tumor cells].
Treupel L; Poupon MF; Couvreur P; Puisieux F
C R Acad Sci III; 1991; 313(3):171-4. PubMed ID: 1913255
[TBL] [Abstract][Full Text] [Related]
19. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
Sun JB; Duan JH; Dai SL; Ren J; Zhang YD; Tian JS; Li Y
Cancer Lett; 2007 Dec; 258(1):109-17. PubMed ID: 17920762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]